{"nctId":"NCT00852371","briefTitle":"Intermittent Preventive Treatment of Malaria in Schoolchildren","startDateStruct":{"date":"2008-02"},"conditions":["Malaria","Intermittent Preventive Treatment"],"count":780,"armGroups":[{"label":"Combination of Amodiaquine +sulfadoxine-pyrimethamine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: amodiaquine + sulfadoxine-pyrimethamine"]},{"label":"Dihydroartemisinin-piperaquine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: dihydroartemisinin-piperaquine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]},{"label":"Sulfadoxine-pyrimethamine alone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: sulfadoxine-pyrimethamine"]}],"interventions":[{"name":"sulfadoxine-pyrimethamine","otherNames":["Fansidar, Roche"]},{"name":"amodiaquine + sulfadoxine-pyrimethamine","otherNames":["Camoquin, Pfizer","Fansidar, Roche"]},{"name":"dihydroartemisinin-piperaquine","otherNames":["Duocotexcin, Holley Cotec Pharmaceuticals"]},{"name":"Placebo","otherNames":["No active ingredient"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥ 8 to \\< 14 years (boys), ≥ 8 to \\< 12 years (girls)\n* Student enrolled at participating school in classes 3-7\n* Provision of informed consent from parent or guardian\n* Provision of assent by student\n\nExclusion Criteria:\n\n* Known allergy or history of adverse reaction to study medications\n* Onset of menstruation (girls)\n* Fever (≥ 37.5°C axillary) or history of fever in the previous 24 hours\n* Evidence of severe malaria or danger signs\n* Haemoglobin \\< 7.0 gm/dL\n* Parasite density \\> 10,000/ul","healthyVolunteers":false,"sex":"ALL","minimumAge":"8 Years","maximumAge":"13 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Risk of Parasitaemia (Unadjusted by Genotyping)","description":"Proportion of participants whose thick blood smears that are positive for asexual parasites","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"87","spread":null},{"groupId":"OG002","value":"164","spread":null},{"groupId":"OG003","value":"147","spread":null}]}]}]},{"type":"SECONDARY","title":"Risk of Recrudescence (Adjusted by Genotyping) in Participants Who Were Parasitaemic at Enrollment","description":"Proportion of participants whose thick blood smears that are positive with the same asexual parasites at baseline and on the day of failure at genotyping","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"64","spread":null},{"groupId":"OG003","value":"50","spread":null}]}]}]},{"type":"SECONDARY","title":"Risk of New Infection (Adjusted by Genotyping) in All Participants","description":"Proportion of participants whose thick blood smears that are positive for new asexual parasites on day of failure at genotyping","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"64","spread":null},{"groupId":"OG003","value":"62","spread":null}]}]}]},{"type":"SECONDARY","title":"Risk of Clinical Failure Due to Recrudescence (Adjusted by Genotyping) in Children Who Were Parasitaemic at Enrollment","description":"Proportion of children who were parasitaemia at enrollment, with subsequent fever and a positive thick blood smear for asexual parasites on the day of failure during follow-up","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"64","spread":null},{"groupId":"OG003","value":"50","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in Haemoglobin","description":"Haemoglobin measured in g/dL; Mean change in haemoglobin calculated as the difference in mean haemoglobin (g/dL) on Day 42 - Day 0, in children treated with the different antimalarial regimens","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":null},{"groupId":"OG001","value":"0.37","spread":null},{"groupId":"OG002","value":"0.24","spread":null},{"groupId":"OG003","value":"0.18","spread":null}]}]}]},{"type":"SECONDARY","title":"Risk of Serious Adverse Events","description":"Any untoward medical occurrence in a participant taking study medication after 14 and 42 days of follow up leading to death, disability, hospitalization or extended hospitalization","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":null},{"groupId":"OG001","value":"122","spread":null},{"groupId":"OG002","value":"125","spread":null},{"groupId":"OG003","value":"114","spread":null}]}]}]},{"type":"SECONDARY","title":"Acceptability of IPT Regimens","description":"Perceived willingness to take study medication as routine preventive treatment","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"67","spread":null},{"groupId":"OG002","value":"20","spread":null},{"groupId":"OG003","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Risk of Clinical Failure Due to Recrudescence (Adjusted by Genotyping) in Children Who Were Parasitaemic at Enrollment","description":"Proportion of children who were parasitaemia at enrollment, with subsequent fever and a positive thick blood smear for asexual parasites on the day of failure during follow-up","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"64","spread":null},{"groupId":"OG003","value":"50","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":198},"commonTop":["Headache","Cough","Nausea","Fever"]}}}